A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

Neoplasia (United States)

Volumn 16, Issue 12, 2014, Pages 1121-1127

  Mehra, Rohit ^a   Shi, Yang ^a,b   Udager, Aaron M ^a   Prensner, John R ^a   Sahu, Anirban ^a   Iyer, Matthew K ^a   Siddiqui, Javed ^a   Cao, Xuhong ^a   Wei, John ^a   Jiang, Hui ^b   Feng, Felix Y ^a   Chinnaiyan, Arul M ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LONG UNTRANSLATED RNA; SCHLAP 1 PROTEIN; UNCLASSIFIED DRUG; RNA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL INVASION; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TISSUE; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR VOLUME; GENETICS; PROCEDURES; PROSTATE TUMOR;

BIOMARKERS, TUMOR; HUMANS; IN SITU HYBRIDIZATION; MALE; NEOPLASM PROTEINS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RNA; RNA, LONG NONCODING;

EID: 85003318605     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.11.006     Document Type: Article

References (28)

1. Udager, A.M., Alva, A., Mehra, R., Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. Cancer J 20 (2014), 29–42.
2. Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo, R., Gingeras, T.R., Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 (2007), 799–816.
3. Kapranov, P., Cheng, J., Dike, S., Nix, D.A., Duttagupta, R., Willingham, A.T., Stadler, P.F., Hertel, J., Hackermuller, J., Hofacker, I.L., et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 316 (2007), 1484–1488.
4. Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M., Zuk, O., Carey, B.W., Cassady, J.P., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458 (2009), 223–227.
5. Prensner, J.R., Chinnaiyan, A.M., The emergence of lncRNAs in cancer biology. Cancer Discov 1 (2011), 391–407.
6. Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29 (2011), 742–749.
7. Prensner, J.R., Iyer, M.K., Sahu, A., Asangani, I.A., Cao, Q., Patel, L., Vergara, I.A., Davicioni, E., Erho, N., Ghadessi, M., et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45 (2013), 1392–1398.
8. Rubin, M.A., Putzi, M., Mucci, N., Smith, D.C., Wojno, K., Korenchuk, S., Pienta, K.J., Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6 (2000), 1038–1045.
9. Shah, R.B., Mehra, R., Chinnaiyan, A.M., Shen, R., Ghosh, D., Zhou, M., Macvicar, G.R., Varambally, S., Harwood, J., Bismar, T.A., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64 (2004), 9209–9216.
10. Gupta, R.A., Shah, N., Wang, K.C., Kim, J., Horlings, H.M., Wong, D.J., Tsai, M.C., Hung, T., Argani, P., Rinn, J.L., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464 (2010), 1071–1076.
11. Kogo, R., Shimamura, T., Mimori, K., Kawahara, K., Imoto, S., Sudo, T., Tanaka, F., Shibata, K., Suzuki, A., Komune, S., et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 71 (2011), 6320–6326.
12. Lai, M.C., Yang, Z., Zhou, L., Zhu, Q.Q., Xie, H.Y., Zhang, F., Wu, L.M., Chen, L.M., Zheng, S.S., Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 29 (2012), 1810–1816.
13. Schmidt, L.H., Spieker, T., Koschmieder, S., Schaffers, S., Humberg, J., Jungen, D., Bulk, E., Hascher, A., Wittmer, D., Marra, A., et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 6 (2011), 1984–1992.
14. Ge, X., Chen, Y., Liao, X., Liu, D., Li, F., Ruan, H., Jia, W., Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol, 30, 2013, 588.
15. Prensner, J.R., Chen, W., Iyer, M.K., Cao, Q., Ma, T., Han, S., Sahu, A., Malik, R., Wilder-Romans, K., Navone, N., et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74 (2014), 1651–1660.
16. Rinn, J.L., Chang, H.Y., Genome regulation by long noncoding RNAs. Annu Rev Biochem 81 (2012), 145–166.
17. Ronnau, C.G., Verhaegh, G.W., Luna-Velez, M.V., Schalken, J.A., Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int, 2014, 2014, 591703.
18. Wapinski, O., Chang, H.Y., Long noncoding RNAs and human disease. Trends Cell Biol 21 (2011), 354–361.
19. Malik, R., Patel, L., Prensner, J.R., Shi, Y., Iyer, M.K., Subramaniyan, S., Carley, A., Niknafs, Y.S., Sahu, A., Han, S., et al. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res 12 (2014), 1081–1087.
20. Prensner, J.R., Zhao, S., Erho, N., Schipper, M., Iyer, M.K., Dhanasekaran, S.M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., Davicioni, E., Den, R.B., Dicker, A.P., Karnes, R.J., Wei, J.T., Klein, E.A., Jenkins, R.B., Chinnaiyan, A.M., Feng, F.Y., RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology 15 (Dec. 2014), 1469–1480, 10.1016/S1470-2045(14)71113-1.
21. Tomlins, S.A., Aubin, S.M., Siddiqui, J., Lonigro, R.J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med, 3, 2011, 94ra72.
22. Mehra, R., Tomlins, S.A., Shen, R., Nadeem, O., Wang, L., Wei, J.T., Pienta, K.J., Ghosh, D., Rubin, M.A., Chinnaiyan, A.M., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007), 538–544.
23. Prensner, J.R., Rubin, M.A., Wei, J.T., Chinnaiyan, A.M., Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med, 4, 2012, 127rv123.
24. Nakanishi, H., Groskopf, J., Fritsche, H.A., Bhadkamkar, V., Blase, A., Kumar, S.V., Davis, J.W., Troncoso, P., Rittenhouse, H., Babaian, R.J., PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008), 1804–1809 [discussion 1809–1810].
25. Whitman, E.J., Groskopf, J., Ali, A., Chen, Y., Blase, A., Furusato, B., Petrovics, G., Ibrahim, M., Elsamanoudi, S., Cullen, J., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180 (2008), 1975–1978 [discussion 1978-1979].
26. Aubin, S.M., Reid, J., Sarno, M.J., Blase, A., Aussie, J., Rittenhouse, H., Rittmaster, R., Andriole, G.L., Groskopf, J., PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184 (2010), 1947–1952.
27. Cooperberg, M.R., Hilton, J.F., Carroll, P.R., The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117 (2011), 5039–5046.
28. Punnen, S., Freedland, S.J., Presti, J.C. Jr., Aronson, W.J., Terris, M.K., Kane, C.J., Amling, C.L., Carroll, P.R., Cooperberg, M.R., Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 65 (2014), 1171–1177.